OCREVUS ZUNOVO
RegisteredWord Mark
•
Ownership
GI
Owner Name
Type: Organization / Corporation
Address
1 DNA Way
South San Francisco, CA 94080
Critical Dates
First Use Date
Sep 25, 2024
Filing Date
Apr 25, 2023
Registration Date
Feb 4, 2025
Mark Descriptions
Goods
Class 5
Pharmaceutical preparations for the treatment of immune diseases and disorders and inflammatory diseases and disorders
Mark Elements
Text Mark
OCREVUS ZUNOVO
Category
Trademark
Standard Characters
Yes
Color Claim
No
Data source: USPTO TSDR
View on USPTO websiteTrademark Timeline
First Use
First Use in Commerce
Filing Date
Publication Date
Registration Date
USPTO Records
Title | Date | Category | Source | Pages | Format | Actions |
|---|---|---|---|---|---|---|
Change Address or Representation Form CAR | Apr 28, 2025 | Incoming | TICRS | 1 | XML | |
Notice of Registration Email ERO(36 KB) | Feb 4, 2025 | Unknown | CMS | 1 | XML | |
Registration Certificate ORC(330 KB) | Feb 4, 2025 | Outgoing | CMS | 1 | PDF | |
TRAM Snapshot of App at Pub for Oppostn (Part 1) PST(57 KB) | Jan 13, 2025 | Unknown | CMS | 2 | XML | |
TRAM Snapshot of App at Pub for Oppostn (Part 2) PST(57 KB) | Jan 13, 2025 | Unknown | CMS | 2 | PNG | |
Notice of Acceptance of SOU - E ESO(31 KB) | Jan 13, 2025 | Unknown | CMS | 1 | XML | |
ITU Unit Action (Part 1) IUA(56 KB) | Dec 14, 2024 | Unknown | CMS | 2 | XML | |
ITU Unit Action (Part 2) IUA(56 KB) | Dec 14, 2024 | Unknown | CMS | 2 | PNG | |
Statement of Use (Part 1) SOU | Oct 3, 2024 | Incoming | TICRS | 3 | XML | |
Statement of Use (Part 2) SOU | Oct 3, 2024 | Incoming | TICRS | 3 | JPEG | |
Statement of Use (Part 3) SOU | Oct 3, 2024 | Incoming | TICRS | 3 | TIFF | |
Specimen SPE | Oct 3, 2024 | Specimens | TICRS | 1 | JPEG | |
ITU Unit Action (Part 1) IUA(52 KB) | Aug 2, 2024 | Unknown | CMS | 2 | XML | |
ITU Unit Action (Part 2) IUA(52 KB) | Aug 2, 2024 | Unknown | CMS | 2 | PNG | |
Extension of Time to File SOU (Part 1) ESU | Aug 1, 2024 | Incoming | TICRS | 2 | XML | |
Extension of Time to File SOU (Part 2) ESU | Aug 1, 2024 | Incoming | TICRS | 2 | TIFF | |
Notice of ITU Extension Approval - E EER(31 KB) | Aug 1, 2024 | Unknown | CMS | 1 | XML | |
Change Address or Representation Form CAR | May 3, 2024 | Incoming | TICRS | 1 | XML | |
Notice of Allowance ALW | Feb 13, 2024 | Outgoing | TICRS | 1 | XML | |
OG Publication Confirmation PB3 | Dec 19, 2023 | Outgoing | TICRS | 1 | XML | |
Notice of Publication NOP | Nov 29, 2023 | Outgoing | TICRS | 1 | XML | |
Notification Of Notice of Publication NON | Nov 29, 2023 | Outgoing | TICRS | 1 | XML | |
TRAM Snapshot of App at Pub for Oppostn (Part 1) PST | Nov 14, 2023 | TRAM Snapshot | TICRS | 2 | XML | |
TRAM Snapshot of App at Pub for Oppostn (Part 2) PST | Nov 14, 2023 | TRAM Snapshot | TICRS | 2 | JPEG | |
XSearch Search Summary XSS(2 KB) | Nov 13, 2023 | XSearch | CMS | 1 | PDF |
AI AssessmentCached Mar 12, 2026, 04:47 AMCached
AI-generated analysis of USPTO data for this trademark. WARNING: Content may not be accurate or up to date. Validate all responses.
Trademark Summary
OCREVUS ZUNOVO is a standard character mark owned by Genentech, Inc., a Delaware corporation located in South San Francisco, California. It covers pharmaceutical preparations for the treatment of immune diseases and disorders and inflammatory diseases and disorders in International Class 005, with additional domestic classes 006, 018, 044, 046, 051, and 052. The mark is registered on the Principal Register as of February 4, 2025, with registration number 7681641 and first use in commerce on September 30, 2024. No active oppositions or legal proceedings are present.
Recent Activity
Filed on April 25, 2023, the application was published for opposition on December 19, 2023, issued a Notice of Allowance on February 13, 2024, and advanced after a Statement of Use was filed on October 3, 2024 and accepted on January 13, 2025. It registered on February 4, 2025, followed by attorney changes on April 28, 2025.
USPTO
AI Analysis
v2.8.0
Never miss important updates for this trademark
Get instant alerts when status changes, similar marks are filed, or renewal deadlines approach